User profiles for D. Jenkins

David JA Jenkins, MD, Ph.D, D.Sc

- Verified email at utoronto.ca - Cited by 90797

Daniel Jenkin

- Verified email at ndm.ox.ac.uk - Cited by 14403

David Paul Jenkins

- Verified email at hw.ac.uk - Cited by 4935

[HTML][HTML] Blockchain technology in the energy sector: A systematic review of challenges and opportunities

…, V Robu, D Flynn, S Abram, D Geach, D Jenkins… - … and sustainable energy …, 2019 - Elsevier
Blockchains or distributed ledgers are an emerging technology that has drawn considerable
interest from energy supply firms, startups, technology developers, financial institutions, …

Colonic health: fermentation and short chain fatty acids

…, CWC Kendall, A Emam, DJA Jenkins - Journal of clinical …, 2006 - journals.lww.com
Interest has been recently rekindled in short chain fatty acids (SCFAs) with the emergence
of prebiotics and probiotics aimed at improving colonic and systemic health. Dietary …

The glycemic index: methodology and clinical implications

TM Wolever, DJ Jenkins, AL Jenkins… - The American journal of …, 1991 - Elsevier
There is controversy regarding the clinical utility of classifying foods according to their
glycemic responses by using the glycemic index (GI). Part of the controversy is due to …

Glycemic index of foods: a physiological basis for carbohydrate exchange

DJ Jenkins, TM Wolever, RH Taylor, H Barker… - The American journal of …, 1981 - Elsevier
To determine the effect of different foods on the blood glucose, 62 commonly eaten foods and
sugars were fed individually to groups of 5 to 10 healthy fasting volunteers. Blood glucose …

[HTML][HTML] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled …

…, A Finn, AL Flaxman, B Hallis, P Heath, D Jenkin… - The Lancet, 2020 - thelancet.com
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

…, EL Franco, C Wheeler, DG Ferris, D Jenkins… - The lancet, 2004 - thelancet.com
Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

Michigan organizational assessment questionnaire

…, C Cammann, D Nadler, D Jenkins - Journal of vocational …, 1979 - psycnet.apa.org
The Michigan Organizational Assessment Questionnaire: Job Satisfaction Subscale (MOAQ;
Lawler et al., 1975) was designed to provide information about the perceptions of …

[HTML][HTML] Sustained efficacy up to 4· 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised …

…, B Romanowski, CM Roteli-Martins, D Jenkins… - The Lancet, 2006 - thelancet.com
Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final …

…, FX Bosch, D Jenkins, K Hardt, T Zahaf, D Descamps… - The Lancet, 2009 - thelancet.com
Background The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was
immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and …

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acuteCampylobacter enteritis and in post-dysenteric irritable …

RC Spiller, D Jenkins, JP Thornley, JM Hebden… - Gut, 2000 - gut.bmj.com
BACKGROUND AND AIMS Post-dysenteric irritable bowel syndrome (PD-IBS) develops in
up to 25% of patients followingCampylobacter enteritis. Our aim was to define the …